Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae  by Nogueira, Keite da Silva et al.
167
Cefepime versus extended spectrum  
b-lactamase-producing Enterobacteriaceae
Authors
Keite da Silva Nogueira1
Alessandra Vale Daur1
Iara Taborda de Messias 
Reason2
Ana Cristina Gales3
Libera Maria Dalla Costa2 
1MSc, Pharmacist, Hospital 
de Clínicas, Universidade 
Federal do Paraná - UFPR, 
Curitiba, Brazil
2PhD, Researcher, Hospital 
de Clínicas, UFPR, 
Curitiba, Brazil
3PhD, Laboratório Alerta, 
Universidade Federal de 
São Paulo, São Paulo, Brazil
Submitted on: 07/21/2010
Approved on: 08/16/2010
Correspondence to: 
Keite da Silva Nogueira
Rua Comendador 
Macedo, 275. Ap.63. 
80060-030 Centro, 
Curitiba, Paraná, Brazil
keitenogueira@ 
hotmail.com
Financial Support: This 
work was supported by 
FUNPAR – Fundação da 
Universidade Federal do 
Paraná (FUNPAR/UFPR).
We declare no conflicts of 
interest.
ABSTRACT
The objective of this study was to evaluate the susceptibility to cefepime of a large group of 
ESBL- producing enterobacteria recently isolated in a Brazilian teaching hospital . The study in-
cluded 280 strains of ESBL-producing enterobacteria, isolated between 2005 and 2008. The pres-
ence of the genes blaCTX-M, blaTEM and blaSHV was determined by PCR and confirmed by nucleo-
tide sequencing. Susceptibility testing for cefepime was performed by disc-diffusion, agar dilution 
method and E-test®. Among the isolates, 34 (12.1%) presented a cefepime inhibition zone ≥ 21 and 
MIC ≤ 8 mg/L by agar dilution and E-strip methods. The use of cefepime for the treatment of infec-
tions caused by ESBL-producing bacteria has been controversial. Some studies of PD/PK show the 
probability of achieving the required PD parameters for cefepime, when the MICs were < 8 mg/L, 
whereas others have reported therapeutic failure with the same MIC. Additional data is essential to 
come to terms about the report and treatment with cefepime in ESBL-producing organisms espe-
cially when these microorganisms are isolated from sterile sites and from critically ill patients. 
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The Clinical Laboratory Standards Institute 
(CLSI) has recommended, in the period of 
2005 to 2009, to perform additional tests for 
the detection of extended-spectrum beta-lac-
tamases (ESBL) production among Escheri-
chia coli, Klebsiella spp. and Proteus mirabilis 
isolates. Strains screened as ESBL-producers 
were reported as resistant to all penicillins, 
cephalosporins, and monobactams, regard-
less of the susceptibility test results. The extra 
step required to perform these tests and the 
increasing prevalence of ESBL among other 
Enterobacteriaceae have lead specialists to find 
an alternative to prevent misuse of cephalo-
sporins. Moreover, clinical studies have dem-
onstrated that the success of cephalosporin 
therapy is more related to the minimum in-
hibitory concentration (MIC) than to the pres-
ence of mechanisms of resistance such as the 
ESBL production. Based on this knowledge the 
European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) and CLSI recom-
mendations have been changed.1,2 In the CLSI 
guideline M100-S20 (2010), new susceptibil-
ity breakpoints were proposed for ceftriaxone 
(≤ 1 µg/mL), cefotaxime (≤ 1 µg/mL), ceftazi-
dime (≤ 4 μ g/mL) and aztreonam (≤ 4 mg/L), 
but not for cefepime (≤ 8 µg/mL).1 According 
to this document, the performance of addition-
al tests for ESBL detection would be no longer 
necessary except for epidemiological or infec-
tion control purposes.1,2
Cefepime, a fourth-generation cepha-
losporin, has been introduced into clinical 
practice in the mid 1990’s.3 It has been rec-
ommended for treatment of Enterobacte-
riaceae infections as it has rapid penetra-
tion through the outer cell membrane and 
is stable against AmpC enzymes. Cefepime 
also demonstrates “in vitro” activity against 
ESBL-producing Enterobacteriaceae. In addi-
tion, the inoculum effect has not been corre-
lated to cefepime MICs in animal models of 
ESBL infections.4 Studies in animal models 
suggest that the cephalosporin pharmacoki-
netic and pharmacodynamic (pK/pD) target 
is similar for the treatment of ESBL- or non-
ESBL-producing pathogens (50% T > MIC). 
Other parameters such as AUC/MIC > 1,654 
and Cmin/MIC > 7.6 also indicated good cor-
relation with clinical cure and bacteriologi-
cal eradication. According to these studies, 
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cefepime current therapeutic dosages would be sufficient 
to reach the PK/PD target. In this manner, it was not nec-
essary to reduce cefepime susceptibility breakpoints.5
The prescription of cefepime for the treatment of 
ESBL infections imposes a serious clinical dilemma. On 
one hand, clinical use of cefepime probably would reduce 
carbapenem consumption. However, treatment failure 
with cefepime has been reported, especially, in nosocomi-
al pneumonia due to ESBL-producing Enterobacteriaceae 
even in those with MICs ≤ 8 mg/L.3 In addition, some 
pK/pD studies show that the probability of achieving 
the pK/pD target with cefepime is lower when the path-
ogen MICs varied from 1 to 8 mg/L. In these cases, to 
achieve the desired pK/pD target, cefepime should be pre-
scribed in prolonged or continuous infusion regimens.5
The main objective of our study was to evaluate cefepime 
susceptibility in a large group of ESBL-producing Enterobac-
teriaceae recently isolated at a Brazilian teaching hospital.
Clinical isolates of ESBL-producing Enterobacteriaceae 
(n = 280) collected from distinct body sites of patients at the 
Hospital of the Universidade Federal do Paraná (HC/UFPR, 
Curitiba, Southern Brazil) were studied. Only a single repre-
sentative of a pulsed field gel electrophoresis (PFGE) pattern 
was included. Species identification was carried out using 
the VITEK system (bioMérieux, Hazelwood, MO). Suscep-
tibility to cefepime was determined by disc-diffusion, agar 
dilution method and E-test® according to CLSI guidelines6 
and manufacturer´s instructions (BioMerieux, Hazelwood, 
MO), respectively. ESBL encoded genes, blaCTX-M, blaTEM or 
blaSHV were analysed by polymerase chain reaction (PCR) 
and DNA sequencing.7 
The cumulative frequency distribution of cefepime is 
shown in Table 1. Among 280 strains of Enterobacteriaceae, 
34 (12.1%) isolates showed cefepime inhibition zones 
≥ 21 mm or MICs ≤ 8 µg/mL by disc-diffusion and agar 
dilution/E-test methods, respectively, and would be clas-
sified as susceptible to cefepime. They were isolated from 
blood (8), cerebrospinal fluid (2), peritoneal fluids (3) and 
urine (21) of patients hospitalized at intensive care units 
(12), surgical wards (9) and other clinics (13). K. pneumo-
niae (64.7%) and E. cloacae (20.6%) were the most frequent 
species susceptible to cefepime. Regarding the ESBL genes 
encoded by the Enterobacteriaceae isolates, blaCTX-M-2 and 
blaSHV-12 were the most frequently detected among isolates 
susceptible to cefepime as depicted in Figure 1. 
Some studies have previously shown that extended-
spectrum beta-lactamases are prevalent in many countries 
around the world, chiefly in South America. Using previ-
ous CLSI guidelines, all those isolates would have been 
considered cefepime-resistant. This recommendation leads 
to increased use of carbapenems and limited the use of 
cefepime in ESBL infections. Our study shows that 12.1% 
of the ESBL-producing Enterobacteriaceae tested were sus-
ceptible to cefepime. This phenotype was found most fre-
quently in SHV-12-producing K. pneumoniae; however, a 
significant number of CTX-M-producing isolates, which are 
Table 1. Minimal Inhibitry concentration of cefepime in ESBL-producing enterobacteria
Microorganisms          Percentage of isolates inhibited at cefepime MIC (mg/L)
 0.06a 0.12b 0.25c 0.5d 1.0e 2.0f 4.0g 8.0h 16.0 32.0 64.0 > 64.0
E. coli - - 4.0 4.0 8.0 8.0 8.0 12.0 36.0 72.0 92.0 100
Klebsiella spp. - 0.8 1.6 1.6 4.9 9.8 13.0 14.6 33.3 53.7 74.0 100
Enterobacter spp. 1.1 1.1 2.2 2.2 3.3 4.4 6.7 7.8 32.2 42.2 54.4 100
Others species - 4.8 4.8 7.1 9.5 11.9 14.3 14.3 45.2 66.7 71.4 100
Total 0.36 1.43 2.50 2.86 5.36 8.21 10.71 12.14 35.0 53.57 68.93 100
cf, cumulative frequency; MIC, minimal inhibitory concentration; --- signs the susceptible breakpoint. Letters a – h represents 
the type of genes found, 1 blaCTX-M-2; b, 1 blaCTX-M-1; 2 blaCTX-M-2; c, 3 blaCTX-M-2; d, 1blaSHV-12; e, 3 blaCTX-M-1; 1 blaCTX-M-2; 1blashv-12; 2blaCTX-
M-2 +blaSHV-12; f, 1 blaCTX-M-2; 3 blaSHV-121 blaCTX-M-9 +blaSHV-5; 3 blaCTX-M-2 + blaSHV-%; g, 2 blaCTX-M-2; 1 blaCTX-M-9; 1 blatem-136; 3 blaSHV-12 ;h, 2 
blaCTX-M-2; 1 blaSHV-5; 1 blaCTX-M-2 +blaSHV-5.
Figure 1: Cefepime susceptible species and groups of ESBL.
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the most prevalent in South America, was also suscepti-
ble to cefepime. In other geographic regions, where group 
TEM or SHV is prevalent, the cefepime susceptibility 
among ESBL-producing isolates might be even higher. In 
North America, 93.8% and 92.0% of the ESBL-producing 
E. coli and -K. pneumoniae, respectively, were susceptible 
to cefepime.8 In Taiwan, Liao et al. reported that 77% and 
73.4% of the ESBL-producing E. coli and K. pneumoniae 
were cefepime susceptible.9 
In this study, 4.8% of ESBL-producing enterobacteria 
isolates have shown MIC ≤ 1 mg/L. PK/PD studies suggest 
that successful outcome using conventional regimens of 
cefepime (50% T > MIC) could be achieved for treatment of 
infections caused by such isolates, regardless ESBL produc-
tion.5 Most authors would consider acceptable the clinical 
use of cefepime in these conditions. However, clinical out-
comes are contradictory for infections caused by isolates, 
in which MICs varied from 1 to 8 mg/L. For infections 
caused by such isolates, pK/pD studies have demonstrated 
that the pharmacodynamic target could be achieved only if 
the infusion time or dosage were modified.4 In this manner, 
EUCAST recommends that only isolates exhibiting MICs 
for cephalosporins, including cefepime, ≤ 1 mg/L must be 
reported as susceptible to cephalosporins, regardless of 
ESBL production.2
Several reports have shown therapeutic failure when 
the patient had received cefepime for treatment of non-
urinary infections caused by ESBL-producing organisms. 
These data indicate that the body site of infection might 
affect cefepime effectiveness.11 In our study, although most 
of the ESBL-producing isolates susceptible to cefepime 
were from urinary tract infections, 38.2% of these iso-
lates were originated from sterile body sites of infection 
and 35% were from critically ill patients, increasing the 
chance of a possible therapeutic failure. In addition, the 
safety of using cefepime has been questioned. A meta-
nalysis study associated the use of cefepime with increase 
in the mortality rates.12 Although this finding has been 
questioned by some authors, other studies have reported 
many untoward effects of this drug.3 Therefore, the pre-
scription of modified cefepime regimens especially those 
using higher doses need more extensive evaluation before 
their use is encouraged. 
At this moment, it would be difficult to consider 
cefepime a safe option for treating ESBL infections, par-
ticularly those caused by isolates with MICs between 1 and 
8 mg/L or cultured from sterile sites and/or from critically 
ill patients. Moreover, the discordance between CLSI and 
EUCAST guidelines may cause confusion among microbi-
ologists and infectious diseases specialists. While the role 
of cefepime in the treatment of ESBL infections is not es-
tablished by clinical studies, compliance with the European 
guidelines seems more appropriate. 
REFERENCES 
1. Clinical Laboratory and Standard Institute. Performance 
Standards for Antimicrobial Susceptibility Testing;Twentieth 
Informational Supplement M100-S20. Pennsylvania: CLSI; 
2010.
2. European Committee on Antimicrobial Susceptibility Testing. 
Breakpoints and expert rules for 3rd and 4th generation cepha-
losporins and Enterobacteriaceae with and without beta-lac-
tam resistance organisms. EUCAST. 2009. 
3. Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in 
an era of increasing antimicrobial resistance. Expert Rev Anti 
Infect Ther 2008; 6:805-24. 
4. Maglio D, Ong C, Banevicius MA et al. Determination of the in 
vivo pharmacodynamic profile of cefepime against extended-
spectrum-beta-lactamase-producing Escherichia coli at vari-
ous inocula. Antimicrob Agents Chemother 2004; 48:1941-7.
5. Lee, S Y, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in 
patients with extended spectrum beta-lactamase (ESBL) and 
non-ESBL infections. J Infect 2007; 54:463-8.
6. Clinical Laboratory and Standard Institute. Performance 
Standards for Antimicrobial Disk Susceptibility Tests; ap-
proved Standard - Tenth Edition document M02-A10. Penn-
sylvania CLSI; 2009. 
7. Payne DJ, Thomsom CJ. Molecular approaches for the detec-
tion and Identification of beta-lactamases. In: Woodford N, 
Johnson AP eds. Molecular Bacteriology: Protocols and Clini-
cal Applications. Totowa: Humana Press. 1998.
8. Sader, H S, Fritsche TR, Jones RN. Potency and spectrum 
trends for cefepime tested against 65746 clinical bacterial 
isolates collected in North American medical centers: results 
from the SENTRY Antimicrobial Surveillance Program (1998-
2003). Diagn Microbiol Infect Dis 2005; 52:265-73.
9. Liao CH, Sheng WH, Wang JT et al. In vitro activities of 16 
antimicrobial agents against clinical isolates of extended-spec-
trum beta-lactamase-producing Escherichia coli and Klebsiella 
pneumoniae in two regional hospitals in Taiwan. J Microbiol 
Immunol Infect 2006; 39:59-66.
10. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical im-
plications of extended spectrum beta-lactamase (ESBL) pro-
ducing Klebsiella species and Escherichia coli on cefepime ef-
fectiveness. J Infect 2005; 51:211-7.
11. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and 
safety of cefepime: a systematic review and meta-analysis. Lan-
cet Infect Dis 2007; 7:338-48.
Nogueira, Daur, Reason et al.
